A Double-Blind, Randomized, Placebo-Controlled Factorial Study to Evaluate the Efficacy and Safety of TAK-475 [lapaquistat] and Simvastatin Alone and in Combination in Subjects With Hypercholesterolemia.

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled Factorial Study to Evaluate the Efficacy and Safety of TAK-475 [lapaquistat] and Simvastatin Alone and in Combination in Subjects With Hypercholesterolemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Lapaquistat; Simvastatin
  • Indications Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Jan 2010 Actual end date (May 2007) added as reported by ClinicalTrials.gov.
    • 14 Jan 2009 Status changed from discontinued to completed, as reported by Clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top